Chronic Obstructive Pulmonary Disease
The Chronic Obstructive Pulmonary Disease pipeline: 63 tracked drugs, 21 approved for this indication.
21 approved / phase 412 Phase 31 Phase 2/318 Phase 21 Phase 1/26 Phase 14 preclinical / unstaged
Compare the share prices of listed companies in Chronic Obstructive Pulmonary Disease →
Total attributable cost
$61.4B
$4,322/patient
Drug spend
Not yet sourced
All severities, diagnosed (2022 estimate) · US
The Chronic Obstructive Pulmonary Disease pipeline
Key trial results for every approved and late-stage drug: Chronic Obstructive Pulmonary Disease results by drug.